Cargando…

Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent

To obtain a tumor cell-selectivity of methyl-β-cyclodextrin (M-β-CyD), we newly synthesized folate-appended M-β-CyD (FA-M-β-CyD), and evaluated the potential of FA-M-β-CyD as a novel anticancer agent in vitro and in vivo. Potent antitumor activity and cellular association of FA-M-β-CyD were higher t...

Descripción completa

Detalles Bibliográficos
Autores principales: Onodera, Risako, Motoyama, Keiichi, Okamatsu, Ayaka, Higashi, Taishi, Arima, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551233/
https://www.ncbi.nlm.nih.gov/pubmed/23346361
http://dx.doi.org/10.1038/srep01104
_version_ 1782256539540652032
author Onodera, Risako
Motoyama, Keiichi
Okamatsu, Ayaka
Higashi, Taishi
Arima, Hidetoshi
author_facet Onodera, Risako
Motoyama, Keiichi
Okamatsu, Ayaka
Higashi, Taishi
Arima, Hidetoshi
author_sort Onodera, Risako
collection PubMed
description To obtain a tumor cell-selectivity of methyl-β-cyclodextrin (M-β-CyD), we newly synthesized folate-appended M-β-CyD (FA-M-β-CyD), and evaluated the potential of FA-M-β-CyD as a novel anticancer agent in vitro and in vivo. Potent antitumor activity and cellular association of FA-M-β-CyD were higher than those of M-β-CyD in KB cells, folate receptor (FR)-positive cells. FA-M-β-CyD drastically inhibited the tumor growth after intratumoral or intravenous injection to FR-positive Colon-26 cells-bearing mice. The antitumor activity of FA-M-β-CyD was comparable and superior to that of doxorubicin after both intratumoral and intravenous administrations, respectively, at the same dose, in the tumor-bearing mice. All of the tumor-bearing mice after an intravenous injection of FA-M-β-CyD survived for at least more than 140 days. Importantly, an intravenous administration of FA-M-β-CyD to tumor-bearing mice did not show any significant change in blood chemistry values. These results strongly suggest that FA-M-β-CyD has the potential as a novel anticancer agent.
format Online
Article
Text
id pubmed-3551233
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35512332013-01-23 Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent Onodera, Risako Motoyama, Keiichi Okamatsu, Ayaka Higashi, Taishi Arima, Hidetoshi Sci Rep Article To obtain a tumor cell-selectivity of methyl-β-cyclodextrin (M-β-CyD), we newly synthesized folate-appended M-β-CyD (FA-M-β-CyD), and evaluated the potential of FA-M-β-CyD as a novel anticancer agent in vitro and in vivo. Potent antitumor activity and cellular association of FA-M-β-CyD were higher than those of M-β-CyD in KB cells, folate receptor (FR)-positive cells. FA-M-β-CyD drastically inhibited the tumor growth after intratumoral or intravenous injection to FR-positive Colon-26 cells-bearing mice. The antitumor activity of FA-M-β-CyD was comparable and superior to that of doxorubicin after both intratumoral and intravenous administrations, respectively, at the same dose, in the tumor-bearing mice. All of the tumor-bearing mice after an intravenous injection of FA-M-β-CyD survived for at least more than 140 days. Importantly, an intravenous administration of FA-M-β-CyD to tumor-bearing mice did not show any significant change in blood chemistry values. These results strongly suggest that FA-M-β-CyD has the potential as a novel anticancer agent. Nature Publishing Group 2013-01-22 /pmc/articles/PMC3551233/ /pubmed/23346361 http://dx.doi.org/10.1038/srep01104 Text en Copyright © 2013, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Article
Onodera, Risako
Motoyama, Keiichi
Okamatsu, Ayaka
Higashi, Taishi
Arima, Hidetoshi
Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent
title Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent
title_full Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent
title_fullStr Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent
title_full_unstemmed Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent
title_short Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent
title_sort potential use of folate-appended methyl-β-cyclodextrin as an anticancer agent
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551233/
https://www.ncbi.nlm.nih.gov/pubmed/23346361
http://dx.doi.org/10.1038/srep01104
work_keys_str_mv AT onoderarisako potentialuseoffolateappendedmethylbcyclodextrinasananticanceragent
AT motoyamakeiichi potentialuseoffolateappendedmethylbcyclodextrinasananticanceragent
AT okamatsuayaka potentialuseoffolateappendedmethylbcyclodextrinasananticanceragent
AT higashitaishi potentialuseoffolateappendedmethylbcyclodextrinasananticanceragent
AT arimahidetoshi potentialuseoffolateappendedmethylbcyclodextrinasananticanceragent